CYP Cocktail clinical trials

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

This study looks at a new drug, zipalertinib, for advanced lung cancer (NSCLC) that has specific gene changes called EGFR Exon 20 insertions or other uncommon mutations. We want to see how safe and effective it is.